慢性乙型肝炎有限治疗:与新型药物类别的类似和不同问题
Marion G Peters1, Man-Fung Yuen2, Norah Terrault3
1Department of Medicine, Northwestern University, Chicago, Illinois, USA.
概括
专家们就停止慢性乙型肝炎 (HBV) 感染的有限治愈疗法达成共识. 本指南涉及试验设计,患者选择以及停止和重新启动HBV治疗的标准.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 临床试验设计 临床试验设计
背景情况:
- 慢性乙型肝炎 (HBV) 影响全球超过2.5亿人,导致肝脏疾病和癌症.
- 目前的治疗方法只能抑制HBV,没有确定的治疗方法.
- 结合多种药物的新型有限疗法正在开发中.
研究的目的:
- 建立关于在临床研究中停止有限HBV治疗的标准的共识.
- 为了指导持续治疗后有效性和安全性的证明.
主要方法:
- 召开了多方利益相关者HBV论坛网络研讨会和工作组讨论.
- 包括来自学术界,临床实践,行业,患者倡导和监管机构的专家.
- 关于终止治疗的关键方面综合的观点.
主要成果:
- 概述了关于有限HBV治疗研究试验设计的共识领域.
- 定义了患者选择,结果和生物标志物的考虑.
- 确定停止治疗,重新治疗和随访时间的标准.
结论:
- 多方利益相关者的共识为评估有限的治疗性HBV疗法提供了一个框架.
- 解决了未来临床试验设计和监管方面的关键问题.
- 突出了在HBV治愈疗法开发中的未满足需求和未来研究方向.
相关概念视频
Hepatic Drug Excretion: Enterohepatic Cycling
1.6K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.6K
Hepatic Drug Clearance: Role of Transporters
83
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
83
Hepatic Drug Excretion: Influencing Factors
152
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
152
Hepatic Drug Clearance: Effect of Protein Binding
241
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
241
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
697
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
697
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
61
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
61


